

## TEST REPORT

Report №.:

**ZDAE2200170 Eb** 

Sample Name:

**Gold Lixiviant** 

Customer:

**Shandong Sino-Gold Mining and Metallurgy** 

Co.,Ltd

Contact Informatio

Block C, Qingdao Expert Academician Entrepreneurship and Innovation Park, No. 600 Jiushui East Road, Laoshan District, Qingdao, Shandong

**Test Type:** ✓ Submitted by Customer ☐ Sampling by NACC

Date for Reporting: 2022-11-

(9)

Institute of Analysis, Guangdong Academy of Sciences(China National Analytical Center, Guangzhou)

### Declaration

- 1) Institute of Analysis, Guangdong Academy of Sciences(China National Analytical Center, Guangzhou), abbreviated to NACC.
- 2) The report is invalid without official seal and signatures.
- 3) This document cannot be reproduced except in full, without prior written approval of NACC. Any copy which has not been stamped again with special seal of NACC is also invalid.
- 4) Report is invalid if being altered, supplemented or deleted.
- 5) For commissioned inspection and testing, report results is responsible only for the sample(s) received.
- 6) Without NACC's written consent, the client or any third party shall not presume to use the report or test results for improper propaganda.
- 7) Any disagreements of report should be fed back to NACC within 15 days upon issuing report. After 15 days, report is considered as accepted by the client.
- 8) The data and result of a test report without the symbol CMA has no social validity, only for internal use of clients.
- 9) Any ambiguity arising from languages used in report, the Chinese language shall prevail.

Address: B2 Building B Zone, Jingyue road No. 6, Zhongshan, China, 528437

Consulting Hotline: (0760)89969681 Fax: (0760)89969681

Complaints hotline: (008620)87686086, 87656074

E-mail: animal@fenxi.com.cn Website: http://www.fenxi.com.cn



# TEST REPORT

Repor	t №.:	ZDAE2200170 Eb						
Sar	mple Name:	Gold Lixiviant	Sample Quantity:	100 g				
Sampl	e Appearance:	powder	Specifications:	1				
Tes	st Category:	Consignment Inspection	Production Date and Sample Lot №./Batch №.:	1				
(	Customer:	Shandong Sino-Gold Mining and Metallurgy Co.,Ltd	Address:	Block C, Qingdao Expert Academician Entrepreneurship and Innovation Park, No. 600 Jiushui East Road, Laoshan District, Qingdao, Shandong				
Ma	nufacturer:		Address:	/				
Da	verificate of Sample Received:	information are provided and confy the accuracy, appropriateness at	nd completeness of that provided	by the client.				
	Item(s):	Acute oral toxicity test	Test Completion Date:	2022-11-04				
	Basis:	GB/T 21603-2008'chemical, ac	cute oral toxicity test method'					
Summ	ary of Results:							
№.	Item		Result	4 10 15 16 16				
1	Acute oral toxic	Ito calculate the LD <sub>co</sub> = 2471 mg / kg ( partial response dose ) with a 95 % confidence						
Remar	ks: Details show	ed on attachment file (P.4-5).						

BLANK BELOW



### **TEST REPORT**

Report №.:	ZDAE2200170 Eb			
Sample Name:	Gold Lixiviant	Date of Sample Received:	2022-10-14	
Item(s):	Acute oral toxicity test	Test Completion Date:	2022-11-04	
1 Commis				

#### 1 Sample

Sample name Gold Lixiviant, powder. The sample was prepared into a suspension with 1 % sodium carboxymethyl cellulose solution as the test substance

#### 2 Test animals in this experiment

11 SPF KM mice, male, weighing 20~22 g, were provided by Zhuhai Bes Test Bio-Tech Co.,Ltd (Laboratory animal production permit No. SCXK(Yue)2020-0051), and the purchase order number was 20220029.

#### 3 Experimental conditions

Our Laboratory animal production permit number is SYXK(Yue)2019-0201. Mice were raised in IVC cages in barrier environment, 5 mice per cage. The facility temperature was between 20°C to 26°C, and the humidity was between 40% to 70%. The feed was provided by Xie Tong Biology Co., Ltd (Feed production permit No. Su Si Zheng(2019)01008). 4 Method

According to GB/T 21603-2008"chemical, acute oral toxicity test method", Up-and-down-procedure was adopted. The first animal is dosed a step below the best preliminary estimate of the LD50. If the animal survives, the second animal receives a higher dose. If the first animal dies or appears moribund, the second animal receives a lower dose. Using the progression of 0.2, doses would be selected from the sequence 175 mg/kg, 280 mg/kg, 440 mg/kg, 700 mg/kg, 1100 mg/kg, 1750 mg/kg, 2800 mg/kg. The toxic manifestation, death number and death time of the animals were recorded. The dead animals and the animals killed at the end of the observation period were anatomized and observed with naked eyes. Observation period of 14 days.  $LD_{50}$  and confidence limit were calculated according to the observation results.

#### 5 Results

See Table 1 Acute Toxicity test record sheet.

(accounts carried forward)



Table 1 Acute Toxicity test record sheet

							Table I Acute Ioxi	city test record s	sneet				
Ani mal num ber	Ani mal Sex	Dosage (mg/kg)	An admi	(g) Day	disse		Poisoning	Time of onset and disappearance of toxic symptoms	Time of death	Anatomical observation	LD <sub>50</sub> 95% confidence interval		
1	male	5000	20	/	20	Oral admin istration	Died after administration.	Died after administration.	Died after administ ration.	No obvious abnormality	Cil		
2	male	175	22	27	32		No obvious abnormality	1	/	No obvious abnormality			
3	male	280	22	28	34		No obvious abnormality	/	/	No obvious abnormality			
4	male	440	20	28	33		No obvious abnormality	/	/	No obvious abnormality	The acute oral toxicity test application software package (AOT425 StatPgm) was used to calculate the LD50 = 2471 mg/		
5	male	700	21	26	33		No obvious abnormality	,		No obvious abnormality			
6	male	1100	20	27	31		No obvious abnormality			No obvious abnormality			
7	male	1750	20	27	32		tion	tion	No obvious abnormality		1	No obvious abnormality	kg ( partial response dose ), with a 95 % confidence interval
8	male	2800	20	/	20		Activity decreased after administration.	Symptoms appear immediately after administration.	30min	No obvious abnormality	of 1750 mg / kg- 2800 mg / kg.		
9	male	1750	20	26	30		No obvious abnormality	/	/	No obvious abnormality	AC		
10	male	2800	22		22		Activity decreased after administration.	Symptoms appear immediately after administration.	30min	No obvious abnormality	99		
11	male	1750	21	26	32		No obvious abnormality	/	/	No obvious abnormality	10		